"WntResearch is an exciting company and I am honoured to have been allowed to participate in the company's development over the last two to three years. WntResearch is in a very strong position today with a strong financial position and an interesting program, which will soon enter Phase 2 clinical trials. I am confident that WntResearch will be able to find a very suitable replacement," says Thomas Feldthus.

"We thank Thomas Feldthus for his contribution to the positive development of the company. We have initiated the process of finding a suitable replacement. In the mean time the CFO tasks will be carried out by our accountant company Innecta with which WntR has collaborated for several years," says Nils Brünner, CEO of WntResearch.

For additional information please contact:
Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.